Inhibition of Folate Metabolism in Chemotherapy

1. Front Matter

   Pages I-XXI

   PDF

2. Trimethoprim/Sulfamethoxazole: An Overview

   1. Trimethoprim/Sulfamethoxazole: An Overview

      • G. P. Wormser, G. T. Keusch

      Pages 1-8

3. Pharmacology and Biochemistry

   1. Front Matter

      Pages 9-9

      PDF

   2. Functions of Tetrahydrofolate and the Role of Dihydrofolate Reductase in Cellular Metabolism

      • G. H. Hitchings

      Pages 11-23

   3. Sulfonamides: Structure-Activity Relationships and Mechanism of Action

      • N. Anand

      Pages 25-54

   4. Dihydrofolate Reductase

      • J. J. Burchall

      Pages 55-74

   5. Antibacterial Activity

      • S. R. M. Bushby

      Pages 75-105

   6. Selective Inhibitors of Bacterial Dihydrofolate Reductase: Structure-Activity Relationships

      • B. Roth

      Pages 107-127

   7. Kinetics of Antibacterial Effects

      • J. K. Seydel

      Pages 129-161

   8. Disposition and Metabolism of Trimethoprim, Tetroxoprim, Sulfamethoxazole, and Sulfadiazine

      • C. W. Sigel

      Pages 163-184

   9. Preclinical Toxicity Testing of Co-trimoxazole and Other Trimethoprim/Sulfonamide Combinations

      • A. D. Dayan

      Pages 185-203

4. Clinical Pharmacology

   1. Front Matter

      Pages 205-205

      PDF

   2. Adverse Effects of Co-trimoxazole

      • D. H. Lawson

      Pages 207-227

   3. Clinical Pharmacokinetics of Co-trimoxazole

      • I. Hansen

      Pages 229-242

   4. Resistance: Genetics and Medical Implications

      • J. F. Acar, F. W. Goldstein

      Pages 243-258

5. Clinical Studies

   1. Front Matter

      Pages 259-259

      PDF

   2. Trimethoprim Alone: Clinical Uses

      • D. W. Barry, K. H. Pattishall

      Pages 261-291

   3. Inhibitors of Dihydrofolate Reductase as Antiprotozoal Agents

      • I. M. Rollo

      Pages 293-307

   4. Pediatric Uses of Sulfonamides, Trimethoprim, and the Combination

      • L. T. Gutman, C. M. Wilfert

      Pages 309-329

   5. Use of Co-trimoxazole in Urinary Tract Infection

      • F. O’Grady

      Pages 331-341

The literature on co-trimoxazole (TMP jSMX) is voluminous, but in the main it consists of research reports. The same can be said of various symposia that have appeared. This volume attempts to present the current status of this antibacterial combination in a series of topical reviews, each of which represents a comprehensive summary of a segment of the field. The editor acknowledges with appreciation the help provided by JACKIE, JENKS, LEE KUYPER, and particularly, RUTH Ross in the preparation of the Subject Index, and thanks Burroughs Wellcome Co. for providing access to library and word processing facilities. Research Triangle Park GEORGE H. HITCHINGS List of Authors Dr. J. F. ACAR, Hospital Saint-Joseph, 7, rue Pierre-Larousse, F-75674 Paris Cedex 14 Dr. N. ANAND, National Information Centre for Drugs and Pharmaceuticals, Central Drug Research Institute, Chattar Manzil, P. O. Box No. 173, Lucknow, 226001jIND Dr. D. W. BARRY, The Wellcome Research Laboratories, Burroughs Wellcome Co. , 3030 Cornwallis Road, Research Triangle Park, NC 27709jUSA Dr. R. E. BLACK, Center for Vaccine Development, University of Maryland, Division of Infectious Diseases, 29 S. Greene Street, Bressler Building, Room 404, Baltimore, MD 21201jUSA Dr. J. J. BURCHALL, Department of Microbiology, The Wellcome Research Laboratories, Burroughs Wellcome Co. , 3030 Cornwallis Road, Research Triangle Park, NC 27709jUSA Dr. S. R. M. BUSHBY, The Wellcome Research Laboratories, Burroughs Wellcome Co. , 3030 Cornwallis Road, Research Triangle Park, NC 27709jUSA Dr. M. L.

• Cotrimoxazol
• biology
• chemotherapy
• drug
• drug research
• infectious disease
• metabolism
• research
• vaccine

• The Wellcome Research Laboratories, Burroughs Wellcome Co., USA

  George H. Hitchings

Policies and ethics